Wednesday, February 04, 2026 General review publication Liu S, Wang D, Robinson A, Mates M, Li Y, Chooback N, Gaudreau P-O, Digby GC, Fung AS, Genta S. Balancing Innovation and Safety: Prediction, Prevention, and Management of Pneumonitis in Lung Cancer Patients Receiving Novel Anti-Cancer Agents. Cancers (Basel) 17: 2522. 2025.https://www.mdpi.com/2072-6694/17/15/2522 Pneumonitis is a potential toxicity of common anti-cancer therapies, including radiotherapy, chemotherapy, immunotherapy, and targeted therapy. Due to underlying disease and comorbidities, lung cancer patients are at high risk of developing fatal cases of pneumonitis or permanent impairment of their respiratory function. Novel anti-cancer agents, including antibody–drug conjugates and bispecific antibodies, have recently been incorporated into clinical use for lung cancer patients due to their demonstrated antitumor activity. However, these medications may be associated with an increased probability of pneumonitis; therefore, implementation of strategies to optimize risk stratification and management of pneumonitis is urgently needed to improve patient care.
